Revenio (R0V) Stock Price & Analysis
R0V Stock Chart & Stats
- Day’s Range
- EUR 10.38 - EUR 10.40
- 52-Week Range
- EUR 9.85 - EUR 20.39
- Previous Close
- EUR 10.32
- Volume
- N/A
- Average Volume (3M)
- 7
- Market Cap
- EUR 436.28M
- Enterprise Value
- EUR 595.91M
- Total Cash (Recent Filing)
- EUR 22.20M
- Total Debt (Recent Filing)
- EUR 2.40M
- Price to Earnings (P/E)
- 21.1
- Beta
- 0.47
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- 0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.55%
Revenio News
R0V FAQ
What was Revenio’s price range in the past 12 months?
What is Revenio’s market cap?
When is Revenio’s upcoming earnings report date?
How were Revenio’s earnings last quarter?
Is Revenio overvalued?
Does Revenio pay dividends?
What is Revenio’s EPS estimate?
How many shares outstanding does Revenio have?
What happened to Revenio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revenio?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Revenio
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Jouni Erik Toijala
- Employees
- 765
- Website
- www.reveniogroup.fi
- Address
- Härkähaankuja 7, Vantaa, UU, 01730, FI
Revenio (R0V) Earnings & Revenues
R0V Earnings Call
Earnings Call SentimentNeutral
The call presented strong progress on the Visionix integration, early realization of the EUR 20 million synergy plan, new commercial opportunities, and FDA clearance for the DRSplus AI solution. However, organic growth was flat, gross margins and profitability declined, operating cash flow was negative, leverage increased following the acquisition, and the iCare ILLUME approval timeline moved later. Overall, the strategic and integration outlook was constructive, but current operating and balance-sheet metrics were mixed.
View all DE:R0V earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |
